[
  {
    "ts": null,
    "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
    "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741625200,
      "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
      "id": 133127786,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220400589/image_1220400589.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Most Undervalued US Stock to Buy According to Hedge Funds?",
    "summary": "We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other undervalued US stocks. On a down day for major market averages, Paul Hickey, co-founder of Bespoke Investment Group, and […]",
    "url": "https://finnhub.io/api/news?id=09db7a3ba805ebf24daa9b46375794ea0cabc7aae8ea4f02767d13b4d4c7e7dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741614043,
      "headline": "Is Pfizer Inc. (PFE) the Most Undervalued US Stock to Buy According to Hedge Funds?",
      "id": 133185275,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other undervalued US stocks. On a down day for major market averages, Paul Hickey, co-founder of Bespoke Investment Group, and […]",
      "url": "https://finnhub.io/api/news?id=09db7a3ba805ebf24daa9b46375794ea0cabc7aae8ea4f02767d13b4d4c7e7dc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?",
    "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform.",
    "url": "https://finnhub.io/api/news?id=7a0d973be1a7d9f57ad97af3e1efd770f81219dd8a93bf7896ba0353a976e397",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741611120,
      "headline": "Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?",
      "id": 133185276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform.",
      "url": "https://finnhub.io/api/news?id=7a0d973be1a7d9f57ad97af3e1efd770f81219dd8a93bf7896ba0353a976e397"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next move.",
    "url": "https://finnhub.io/api/news?id=6e0d34780507c8c6e789f92af39697e43c29a844b05e7905df9e064d4a2018cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741597605,
      "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
      "id": 133185278,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next move.",
      "url": "https://finnhub.io/api/news?id=6e0d34780507c8c6e789f92af39697e43c29a844b05e7905df9e064d4a2018cd"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech guides for worse-than-expected 2025 revenue decline",
    "summary": "German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros and 2.2 billion euros, prompting a decline in its share price. ...",
    "url": "https://finnhub.io/api/news?id=be027d5c1999c0b5ebc99172825c964dc932d317316060d942a105dc378a97c5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741595510,
      "headline": "BioNTech guides for worse-than-expected 2025 revenue decline",
      "id": 133117107,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros and 2.2 billion euros, prompting a decline in its share price. ...",
      "url": "https://finnhub.io/api/news?id=be027d5c1999c0b5ebc99172825c964dc932d317316060d942a105dc378a97c5"
    }
  }
]